Expanded Access Policy

Diamyd Medical is committed to developing new therapies to address the unmet medical needs of patients suffering from autoimmune diabetes.

Diamyd Medical is currently developing the late-stage investigational medicine Diamyd® for the treatment of Type 1 Diabetes. Our goal is to provide access to our investigational medicine at the appropriate time and in a manner that is most beneficial for patients. We believe that participation in one of our clinical trials is the safest and most effective way to achieve this goal.

We recognize that some patients will not be eligible for our clinical trials and may wish to access our investigational medicine through expanded access. Regrettably, at this time, we are unable to make investigational medicines available outside of a clinical trial.

Diamyd Medical encourages all patients and physicians to visit the clinical trial section of our website at https://www.diamyd.com/docs/clinicalTrials.aspx or visit www.clinicaltrials.gov to find more information about ongoing clinical trials.

Diamyd Medical may revise its expanded access policy in the future.

If you have any questions about our clinical trials, please reach out to us at clinicaltrials@diamyd.com. You can find further contact details on the Contact Us page on our website (https://www.diamyd.com/docs/Contact.aspx).

Last updated on February 23, 2024

Order GAD for preclinical research